Loading...
Market
What will be the outcome of CD&R's acquisition of Sanofi's 50% stake in Opella by end of 2024?
2
Resolution / Starting Odds
Completed • 25%
Delayed • 25%
Cancelled • 25%
Renegotiated • 25%
Press releases from Sanofi or CD&R, major financial news outlets
Story
Sanofi Nears €15.5 Billion Sale of 50% Stake in Opella to CD&R
Oct 11, 2024, 04:44 AM
Sanofi is nearing a significant deal to sell a 50% controlling stake in its consumer health unit, Opella, to Clayton Dubilier & Rice (CD&R). The transaction, valued at approximately €15.5 billion ($16 billion), is poised to be one of the largest deals of the year. CD&R has reportedly outbid rivals, including a consortium led by PAI Partners, to secure this acquisition. The sale, estimated at €15 billion, is seen as a critical health check for mega leveraged buyouts (LBOs) and underscores the growing interest in the consumer health sector.
View original story
Similar markets
Yes • 50%
No • 50%
Healthcare sector • 25%
Technology sector • 25%
Consumer goods sector • 25%
Other sector • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than €15 billion • 25%
€15 billion to €15.5 billion • 25%
€15.5 billion to €16 billion • 25%
More than €16 billion • 25%
Mostly Positive • 25%
Mostly Negative • 25%
Mixed • 25%
Neutral • 25%
Completed Sale • 25%
Talks Abandoned • 25%
Ongoing Negotiations • 25%
Other Outcome • 25%
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by more than 10% • 25%
Amazon • 25%
Apple • 25%
Google • 25%
Other • 25%
Goldman Sachs • 25%
J.P. Morgan • 25%
Morgan Stanley • 25%
Other • 25%
Sale completed • 33%
Negotiations fail • 33%
Negotiations extended • 34%
Increases stake • 25%
Maintains stake • 25%
Reduces stake • 25%
Exits stake • 25%